Editorials Leukotriene modifiers in the treatment of asthma BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7140.1257 (Published 25 April 1998) Cite this as: BMJ 1998;316:1257 Article Related content Metrics Responses Peer review Related articles Editor's Choice Drugs: good, bad, and failing Published: 25 April 1998; BMJ 316 doi:10.1136/bmj.316.7140.0 See more Constitutional symptoms in a young person BMJ December 07, 2016, 355 i5781; DOI: https://doi.org/10.1136/bmj.i5781 An adolescent with disabling abdominal pain BMJ December 07, 2016, 355 i6101; DOI: https://doi.org/10.1136/bmj.i6101 Andrew Wakefield calls Trump “on our side” over vaccines after meeting BMJ December 05, 2016, 355 i6545; DOI: https://doi.org/10.1136/bmj.i6545 Doctors in Pakistan call for workers deported from the UAE to be screened for HIV BMJ December 05, 2016, 355 i6544; DOI: https://doi.org/10.1136/bmj.i6544 Communicating risk to patients in the emergency department BMJ December 05, 2016, 355 i6437; DOI: https://doi.org/10.1136/bmj.i6437 Cited by... Eosinophilic oesophagitis: treatment using MontelukastFulltext PDF Eosinophilic oesophagitis: a novel treatment using MontelukastFulltext PDF Abstract Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukastFulltext PDF Abstract Churg-Strauss syndrome associated with montelukast therapyFulltext PDF Abstract Difficult asthma or Churg-Strauss syndrome?Fulltext PDF Abstract {blacktriangledown}Montelukast and {blacktriangledown}zafirlukast in asthmaFulltext PDF Abstract
